Gene Therapy Development for Cardiovascular Disease
Cardiovascular disease (CVD) is a class of diseases related to the heart or blood vessels and remains a large global health problem today. Although some conventional small-molecule treatments are available for common cardiovascular problems, it's still necessary to develop more efficient approaches to meeting the clinical needs. In many preclinical and clinical researches, gene therapy strategies manifest as a potential treatment option for acquired and inherited cardiovascular diseases. With the help of world first-class technology platforms and skillful scientific teams in the field of biomedicine, Creative Biolabs provides reliable and high quality gene therapy development services for CVD treatment. Our services based on gene therapy include heart failure, vein graft failure, severe cardiac and peripheral ischemia, and some forms of dyslipidemias, etc. Some potential targets for cardiovascular gene therapy are as follows:
Figure 1. Potential Targets for Cardiovascular Gene Therapy (Herttuala 2017)
Potential Targets for Cardiovascular Gene Therapy Development
-
Cardiac Targets
CVD is a general term for conditions affecting the heart or blood vessels and the mainly related diseases caused by the abnormal cardiac function, such as coronary heart disease, restenosis, in-stent restenosis, heart failure and arrhythmias, etc. In some studies, gene therapy has been used during bypass surgery and via minithoracotomy using epicardial injections and obtained promising results. The clinical trials have tested adeno-associated virus-sarcoplasmic reticulum calcium ATPase 2a in patients with chronic systolic heart failure or non-ischemic cardiomyopathy. Various robust CVD models and assay systems have been used in-house and our customized service is designed to select the most appropriate methods to advance your cardiovascular gene therapy development programs.
-
Peripheral Targets
Another potential therapeutic target is used for the peripheral vascular disease caused by atherosclerotic occlusions in the main lower extremity arteries. Current pharmacological approaches are not effective for the treatment of critical limb ischemia or severe peripheral arterial disease. Gene therapy has emerged as a novel option for the peripheral vascular disease and VEGF-A gene therapy has received some positive reports. Moreover, a plasmid-based VEGF-A product has been approved for clinical use in peripheral arterial disease in Russia. Faced with the increasing requirements of gene therapy, Creative Biolabs can design and operate a full range of peripheral vascular disease development services, such as critical limb ischemia and insufficient ulcer healing.
-
Systemic and Liver Targets
Gene therapy can potentially be used for the treatment of hyperlipidemias, lipoprotein metabolism, and atherosclerosis. An approved gene drug (Glybera) based on the AAV1 vector expressing lipoprotein lipase has achieved promising results in lipoprotein lipase deficient patients. Currently, an AAV vector expressing low-density lipoprotein (LDL) receptor is planned to treat homozygous familiar hypercholesterolemia in clinical trials. Some dyslipidemias and even atherosclerosis can also be treated by gene transfer to increase apolipoprotein A-1 levels, which is a key component in antiatherogenic high-density lipoprotein (HDL) particles.
Creative Biolabs has been occupied in the research of biomedical technology for more than ten years. We focus on the field of gene therapy with a strong platform and professional team that can help you with CVD development. If you are interested in our service, please contact us by e-mail and our team will get back to you as soon as possible.
Reference
- Ylä-Herttuala, S. and Baker, A. (2017). Cardiovascular Gene Therapy: Past, Present, and Future.
- Rissanen, T. and Ylä-Herttuala, S. (2007). Current Status of Cardiovascular Gene Therapy. Molecular Therapy, 15(7), pp.1233-1247.
